Medtronic (MDT) Closes In on Dividend King Status After 49 Years

Medtronic (MDT stock page) raised its quarterly dividend to $0.72 a share in June 2026, extending its streak of annual increases to 49 years. The company now needs one more raise to join the Dividend Kings, a group of stocks with 50 consecutive years of payout growth. The $2.88 annualized dividend yields roughly 3.2% at a share price near $91, a solid income return for a large-cap healthcare company.

The dividend record is backed by steady cash flow. In fiscal 2026, Medtronic generated $7.33 billion in operating cash flow, up 4.1% from the prior year. Free cash flow reached $5.43 billion, up 4.6%. The company paid about $3.64 billion in dividends, leaving free cash flow coverage of 1.5 times. The remaining cash went toward capital spending and debt reduction. Medtronic ended the fiscal year with $9.2 billion in cash and investments.

The free cash flow margin came in at about 15% of revenue, a level that provides a buffer for the dividend even if revenue growth slows. The company has maintained a free cash flow payout ratio below 70% for the past five years.

The business that supports the payout is showing stronger momentum. Revenue rose 8.4% to $36.4 billion, the fastest annual growth in a decade. Organic revenue increased 5.8%. A standout was Cardiac Ablation Solutions, where global revenue jumped 78% in the fourth quarter. U.S. revenue in that segment surged 124%. Management has pointed to several newer platforms – Affera, Symplicity, Hugo, Altavista, Stealth AXiS – as drivers of future growth. The Hugo robotic surgery system is in early commercial stages, and Symplicity is a renal denervation device for hypertension. Both are in the early commercial phase but could add to revenue over time.

The dividend growth rate has been modest in recent years. The 1.4% increase in 2026 followed a 1.4% increase in 2025. For income investors looking for fast-growing payouts, this is not the stock. For those seeking reliability, the record speaks for itself.

The outlook for fiscal 2027 gives further reason for dividend investors to hold the stock. Medtronic expects organic revenue growth of 6.75% to 7.25% and adjusted earnings per share of $5.90 to $6.00. At the midpoint of that range, the payout ratio would be about 48%, well within the range that supports continued dividend increases. The company does not need double-digit earnings growth to keep raising the payout. Its debt load is manageable. Medtronic ended the year with about $23 billion in total debt. Its net debt-to-EBITDA ratio was roughly 2.5 times, within investment-grade territory.

AlphaScala’s proprietary score for MDT stands at 54 out of 100, a Mixed rating. The score reflects the company’s solid cash flow and dividend record balanced against modest growth expectations and a high debt load. The dividend is the centerpiece of the investment case. The broader business improvement adds a layer of conviction. The score is neutral. Strengths include yield and consistency. Weaknesses include valuation and growth momentum.

The risk for dividend investors is not the payout itself. The dividend is well covered and the company has a long history. The risk is that the stock’s performance may lag if growth in newer businesses does not accelerate. Medtronic carries a sizable debt of about $23 billion. The cash flow generation is sufficient to service it.

Medtronic is one increase away from a 50-year dividend streak. That milestone would be an achievement. The more important measure is the cash flow and growth that support the payout. With revenue and earnings on an upward trend, the company appears positioned to continue raising the dividend for the foreseeable future. The next dividend decision is due in June 2027, which would mark the 50th consecutive increase.